HOME >> BIOLOGY >> NEWS
UC San Diego supercomputer simulations may pinpoint causes of Parkinson's, Alzheimer's diseases

Using the massive computer-simulation power of the San Diego Supercomputer Center (SDSC) at UC San Diego, researchers are zeroing in on the causes of Parkinsons disease, Alzheimers disease, rheumatoid arthritis and other diseases.

A study published in this weeks Federation of European Biochemical Societies (FEBS) Journal offers for the first time a model for the complex process of aggregation of a protein known as alpha-synuclein, which in turn leads to harmful ring-like or pore-like structures in human membranes, the kind of damage found in Parkinsons and Alzheimers patients.

The researchers at SDSC and UC San Diego also found that the destructive properties of alpha-synuclein can be blocked by beta-synuclein a finding that could lead to treatments for many debilitating diseases.

The current journals cover features an image from the research that helps illustrate the scientists work.

This is one of the first studies to use supercomputers to model how alpha-synuclein complexes damage the cells, and how that could be blocked, said Eliezer Masliah, professor of neurosciences and pathology at UC San Diego. We believe that these ring- or pore-like structures might be deleterious to the cells, and we have a unique opportunity to better understand how alpha-synuclein is involved in the pathogenesis of Parkinsons disease, and how to reverse this process.

Igor Tsigelny, project scientist in chemistry and biochemistry at UC San Diego and a researcher at SDSC, said that the teams research helped confirm what researchers had suspected. The present study using molecular modeling and molecular dynamics simulations in combination with biochemical and ultrastructural analysis shows that alpha-synuclein can lead to the formation of pore-like structures on membranes.

In contrast, he said, beta-synuclein appears to block the propagation of alpha-synucleins into harmful structures.

The complex calculations
'"/>

Contact: Paul K. Mueller
pkmueller@ucsd.edu
858-534-8564
University of California - San Diego
22-Mar-2007


Page: 1 2

Related biology news :

1. Revelle family endows UC San Diego chair honoring Roger Revelle
2. Ocean observing contracts awarded to UC San Diego and University of Washington
3. Latest plant health research to be presented in San Diego
4. San Diego stem cell consortium tops in state funding
5. University of Colorado influenza chip licensed by Quidel Corp. of San Diego
6. University of California, San Diego-led team discovers how we detect sour taste
7. Burnham Institute for Medical Research & UC San Diego establish Joint Center for Molecular Modeling
8. UC San Diego biologists solve plant growth hormone enigma
9. UC San Diego scientists chart rapid advances of fluorescent tools for life-science research
10. UC San Diego partners with Venter Institute to build marine microbial genomics cyberinfrastructure
11. UC San Diego undergraduates do cyberinfrastructure research in Asia, Australia

Post Your Comments:
(Date:5/23/2013)... Rollins School of Public Health at Emory University, ... Technology, have received a $4 million grant over ... Emory University (Health and Exposome Research Center: Understanding ... center grant awarded in the United States. ... National Institute of Environmental Health Sciences (NIEHS) of ...
(Date:5/23/2013)... for the overall health, development, and academic success ... in ensuring that all students have opportunities to ... of vigorous or moderate-intensity physical activity, says a ... Recent estimates suggest that only about half of ... better health and development. The report recommends ...
(Date:5/23/2013)... treating cerebral palsy with autologous cord blood. Following a ... old boy had been in a persistent vegetative state ... after treatment with the cord blood containing stem cells, ... child learned to speak simple sentences and to move. ... dispel the long-held doubts about the effectiveness of the ...
Breaking Biology News(10 mins):Emory, Georgia Tech receive first human exposome center grant in US 2Emory, Georgia Tech receive first human exposome center grant in US 3Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2
(Date:5/24/2013)... BOSTON and TEL AVIV, Israel ... ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in ... , the Company,s President and Chief Executive Officer, and ... will participate in the Benchmark Company, LLC One-on-One Investor Conference ... East Wisconsin Ave., Milwaukee, WI. ...
(Date:5/24/2013)... May 24, 2013 Many factors impact ... uptake or efflux transporters at the blood-tissue barrier. Even ... to unbound fractions in the tissue rather than the ... disposition challenges is required to guide lead optimization, predict ... any species-dependent variables that may impact the likely human ...
(Date:5/24/2013)... 2013 Quincy Bioscience, a leading ... of calcium-binding proteins to support healthy living, is ... study of apoaequorin in Food and ... the British Industrial Biological Research Association. , ... potential adverse effects, if any, of apoaequorin, in ...
(Date:5/23/2013)... 2013 Venaxis, Inc. (Nasdaq:   APPY), an ... FDA clearance and commercializing its rapid, protein biomarker-based appendicitis ... an underwritten public offering of 10,000,000 shares of its ... of its common stock at an exercise price of ... of $1.25 per share and related warrant.  Venaxis has ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3
Cached News: